Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

Inclusion Criteria: * Laboratory confirmed SARS-CoV-2 by positive RT-PCR on any respiratory sample; * Age ≥ 18 years; * Require hospital admission for COVID-19 pneumonia as defined by the presence of pulmonary infiltrates on chest x-ray; * Moderate to severe Covid-19 disease, defined as: SpO2 ≤ 93% on room air; plus requiring non-invasive oxygen therapy (WHO R\&D BOSCI 4 or 5 * Signed informed consent; * Pregnant women will be allowed to participate. Exclusion Criteria: * Current participation in another therapeutic clinical trial for COVID-19; * Invasive mechanical ventilation; * Expected survival \< 24 hours based on clinical assessment (however, the study does not exclude critically ill patients who are not, due to resource limitations, candidates for critical care admission and/or mechanical ventilation); * Known hypersensitivity to immunoglobulin or any components of the formulation;